Semnurpharma - Getting back to normalSemnurpharmaSemnurpharmaSemnurpharma

Getting back to normal

  • About
    • Overview
    • Leadership Team
    • Board of Directors
    • Our Culture
  • Partners
  • Chronic Back Pain
    • Chronic Back Pain
    • SP-102 (SEMDEXA™)
    • About our Studies
      • Phase 3 C.L.E.A.R.-2 Study
      • Phase 3 C.L.E.A.R. Study
      • Phase 2 Repeat Dose Study – SP102-03
      • Phase 1 PK/PD and Safety Study – SP-102
      • Pre-Clinical Study – SP-102
  • Science
    • Technology
    • Publications
    • Clinical Trials
  • Investors
    • Investor Overview
    • Presentation
    • News and Events
    • SEC Filings
    • Governance
    • Analyst Coverage
    • Contact Investor Relations
    • Stock Information
  • Join Our Team
  • Contact Us

News

03
Sep
Date September 3, 2024

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Announce Signing of a Merger Agreement for a proposed Business Combination, Providing for a Pre-Transaction Equity Value of Semnur of $2.5 Billion

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding C...
Read More
Author Jitendra Jadhav
02
Jul
Date July 2, 2024

Semnur Pharmaceuticals, Inc., a Wholly Owned Subsidiary of Scilex Holding Company, and Denali Capital Acquisition Corp. (Nasdaq: DECA) Enter into a Letter of Intent for a Proposed Business Combination

Semnur Pharmaceuticals, Inc. (“Semnur”), a wholly owned subsidiary of Scilex Holding Company ...
Read More
Author uferes@scilexholding.com
02
Nov
Date November 2, 2023

Scilex Holding Company Announces Positive Type C Meeting with the FDA and Reaches Agreement on Path Forward to File an NDA for SP-102 (SEMDEXATM) in Lumbosacral Radicular Pain (Sciatica)

...
Read More
Author uferes@scilexholding.com
05
May
Date May 5, 2022

Results from a Pivotal Phase 3, DB, R, Placebo-controlled, Multicenter Trial of SP-102, a Novel Dexamethasone Injectable Formulation, for the Treatment of Patients with Lumbosacral Radiculopathy (Sciatica)

...
Read More
Author uferes@scilexholding.com
18
Mar
Date March 18, 2022

Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., Announces Final Results for SP-102 (SEMDEXA™) Efficacy and Safety from its Pivotal Phase 3 Clinical Trial Program for Sciatica Pain Management Supporting the Potential for First to Market Opportunity

...
Read More
Author uferes@scilexholding.com
09
Dec
Date December 9, 2021

Scilex Holding Company, a Sorrento Therapeutics, Inc. Subsidiary, Announces Highly Significant Positive Top-Line Results from its Phase 3 Non-Opioid Injectable SP-102 (SEMDEXA™) Pivotal Trial C.L.E.A.R. Program for Sciatica Pain Management

...
Read More
Author uferes@scilexholding.com
07
Oct
Date October 7, 2020

Scilex Holding Company, a Subsidiary of Sorrento Therapeutics, Announces Continuous Sales Growth in ZTlido® and Expects to Complete Enrollment on its SP-102 (SEMDEXA™) Phase 3 Pivotal Trial Program in 2020« back

...
Read More
Author uferes@scilexholding.com
20
Jul
Date July 20, 2020

Scilex Holding Company, a Sorrento Company, Announces Complete Enrollment on Non-Opioid Injectable SP-102 (SEMDEXA™) Phase 3 Pivotal Trial C.L.E.A.R. Program For Sciatica Pain Management

...
Read More
Author uferes@scilexholding.com
27
Mar
Date March 27, 2019

Scilex Holding, a Subsidiary of Sorrento Therapeutics, Announces Phase 2 Trial Results for its Leading SP-102 Program

Complete Enrollment of Phase 2 Trial to Characterize the Pharmacodynamics and Safety of Repeat Dose...
Read More
Author uferes@scilexholding.com
22
Mar
Date March 22, 2019

Sorrento Therapeutics Announces the Merger of Scilex and Semnur to Create a Global Leader in Non-Opioid Pain Management

Semnur’s SP102, addressing multi-billion dollar unmet market needs, in Pivotal Phase 3 Trial with...
Read More
Author uferes@scilexholding.com
1 2 Next page

 

  • Overview
  • Partners
  • Our Culture
  • Product
  • Publications
  • Join Our Team
  • Presentation
  • Contact Us

Connect, follow and have a conversation with us

  • 960 San Antonio Road, Palo Alto, CA, 94303
  • (650) 516-4310
  • info@semnurpharma.com

Privacy Policy | Terms of Use | © 2025 All rights reserved.

Semnur Pharmaceuticals, Inc. (“Semnur”), a Majority-Owned Subsidiary of Scilex Holding Company (Nasdaq: SCLX, “Scilex”), and Denali Capital Acquisition Corp. Announce the Closing of Their Previously Announced Business Combination

Check Our Press Release

Scilex Holding

Semnur Pharmaceuticals

Denali Capital

Reference:
@srinipillay 2016:https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

… heavy objects, or some other non-specific back injury.

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537

The overall estimated number of epidural steroid injection (ESI) procedures in the U.S. is approximately 12.1 million across all Medicare and private coverage patients, with lumbar radiculopathy/sciatica procedures comprising approximately 88% of all ESIs administered, according to a proprietary study by Syneos Health. *

References:
*  Syneos Health

Reference:
@srinipillay 2016: https://www.health.harvard.edu/blog/psychology-low-back-pain-201604259537